Patient A who was exposed to a critical dose of radiation developed skin lesions throughout the body surface, gastrointestinal disorder with massive diarrhea and prominent bleeding, which caused severe loss in body fluids. Gastrointestinal bleeding due to the deteriorated intestinal mucosa was considered to be one of the major causes of death, although infection did not develop, possibly because of SDD and aseptic intensive care, until terminal stages. Patient A ultimately developed respiratory and renal failure in addition to skin exudate and gastrointestinal bleeding, and died of multiple organ failure on the 83rd day after exposure. The extreme unevenness of the dose distribution and the neutron versus γ -ray component made the clinical manifestation very complicated. Initially, the mean absorbed dose was calculated as 16-20 GyEq for Patient A, mainly based on neutron-activated 24 Na in the blood. However, a very recent calculation showed that the absorbed skin dose was highest at the upper-right abdomen reaching 61.8 Gy (27.0 as neutron plus 34.8 Gy as γ -ray). The dorsal side was calculated to have received one eighth of the value of the abdominal side, and much smaller neutron component. His absorbed-dose distribution throughout the body was very inhomogeneous because of the closeness of the standing point to the mixing tank. Despite prolonged survival because of intensive care with massive fluids and blood transfusion, peripheral blood stem-cell transplantation, cultured skin-cell grafts, and the administration of cytokines for marrow, the patient was not saved. Restoration of the bone marrow function, prevention of skin fibrosis, radiation lung damage, and repair of gastrointestinal mucosa, and final recovery of the patient were elusive. Abundant personnel and resources were also a prerequisite to allow for the comprehensive and collective intensive care. A further understanding of the effects of high-dose radiation as well as the basic and clinical development of regeneration medicine are important issues for the future.
INTRODUCTION
The Tokai-mura nuclear accident occurred on September 30, 1999 , at a nuclear fuel-processing facility run by JCO, an affiliate of Sumitomo Metal Mining, in Tokai-mura (70 miles northeast of Tokyo) as a result of an attempted shortcut in the protocol for processing nuclear fuel [1] [2] [3] .
Limited information and literature on clinical management for patients exposed to high levels of radiation necessitated our best judgement on a daily basis for clinical management.
In the present report, we have summarized clinical signs and symptoms, as well as the treatment given for the acute-radiation syndrome of a victim of the Tokai-mura nuclear accident (the patient is referred to as Patient A hereafter). We discuss the case while reviewing past reports on the treatment of accidentally irradiated victims.
SUMMARY OF THE CLINICAL COURSE AND TREATMENT
The patient was a 35 year old married man. He was irradiated critically, when a nuclear reaction was set off, while holding a funnel to pore a uranium solution into a tank at the Tokaimura nuclear fuel-processing plant (Ibaraki, Japan) 1~3) . Shortly following exposure, he had a transient loss of consciousness, followed by vomiting and diarrhea, which were suggestive and consistent with early symptoms of high-dose radiation exposure. Because of the possible high-dose exposure the patient was transferred on the same day from the local National Mito hospital (Ibaraki, Japan) to the National institute of Radiological Science (NIRS, Chiba, Japan) for an extensive diagnostic evaluation and treatment. An anesthesiologist who had transported the patient from Ibaraki to Chiba described his status as "totally exhausted 4) ". At the time of the initial examination, the patient's skin was swollen, similar to a case of severe sunburn (first-degree burn). The face was edematous as well as the right upper extremity, which was the side toward the radiation source 3) . At approximately six hours after exposure, the patient developed mild hypoxemia. NIRS estimated at that time, mainly based on 24 Na in the blood, that the mean whole-body absorbed dose was [16] [17] [18] [19] [20] GyEq as a mixture of neutron and gamma ray, although a very recent calculation showed that his absorbed-dose distribution through the body was very inhomogeneous because of the closeness of the standing point to the mixing tank. His absorbed skin dose was highest at the right upper abdomen, reaching 61.8 Gy (27.0 as neutron plus 34.8 Gy as γ -ray), while the dorsal side received one eighth of that of the abdominal side, and had a much smaller neutron component (Table 1) 1) . On the third day, complicated by oligouremia, fluid was administered in accordance to the protocol for severe-burn patients, and the patient was transferred to the University of Tokyo Hospital (Tokyo, Japan) and placed under intensive care. The patient's peripheral blood lymphocyte count was already at null levels. From the estimated absorbed dose and the declining profile of the peripheral lymphocyte count, the patient was indicated for early hematopoietic stem-cell transplantation and intensive care under aseptic conditions with SDD (selective digestive The data are from NIRS (National Institute of Radiological Science)
1)
The initial estimation was mainly based on 24 Na in the blood, showing mean wholebody absorbed dose of 16-20 GyEq as a mixture of neutrons and γ -rays. A very recent calculation has indicated that his absorbed dose distribution throughout the body was so inhomogenous because of the closeness of the standing point to the mixing tank. The absorbed skin dose was highest at the upper-right abdomen, reaching 61.8 Gy (27.0 as neutron plus 34.8 Gy as gamma ray), while the dorsal side received one eighth of the value of the abdominal side, and a much smaller neutron component 1) . decontamination).
On the seventh and eighth days after exposure, the patient underwent peripheral blood stemcell transplantation (PBSCT) from an HLA-identical female who was an immediate family member (Table 2a , b, Fig. 1 ). Against bone-marrow suppression, hematopoietic factors, including granulocyte-colony-stimulating factor (GCSF), granulocyte/macrophage-colony-stimulating factor (GM-CSF), thrombopoietin (TPO), and erythropoietin (EPO) were administered in addition to peripheral blood stem-cell transplantation. A bone-marrow biopsy on the 17 th day after exposure showed growth of the grafted stem cells. No overt clinical signs specific to graft-versus-host disease were observed. Fluids exceeding 4000 ml/day were administered from immediately after exposure. The patient developed aggravating pulmonary edema despite aggressive diuretic therapy, and hypoxemia required intubation and ventilator-assisted respiratory management. Although the patient required ventilation until his death, signs of radiation lung damage, like fibrosis, did not appear except for pulmonary edema and fever.
The patient showed an uneven distribution of lesions, consistent with the fact that he had been irradiated with the radiation source at his right-frontal side 1) . The location and degree of skin and gastrointestinal lesions correlated with the direction and amount of radiation. Skin lesions throughout the body surface were prominent, and exposure of the sub-epidermal layers due to high-level irradiation caused a severe loss of body fluids.
Intravenous administration of the intestinal mucosa proliferative agent, L-glutamine, was initiated early in the course of the treatment. However, massive diarrhea redeveloped by the 4 th day after exposure, and further increased gastrointestinal bleeding began on the 7 th day after exposure, which lasted until the time of death. Due to the excessive loss of body fluids from skin lesions and gastrointestinal bleeding, the patient continuously required fluid administration, which was increased to a value exceeding 10,000 ml/day, as well as blood transfusions (RBC, fresh frozen plasma, and platelet). The platelet level was maintained at over 30 thousands per mm 3 . Gastrointestinal bleeding due to the deteriorated intestinal mucosa was one of the suspected causes 
DISCUSSION AND EVALUATION OF THE CASE AND TREATMENT
Early guidelines for the diagnosis and treatment of Acute Radiation Syndrome were developed by Drs. Niel Wald (University of Pittsburg) and George Thoma (St. Louis University), who analyzed 31 cases of ARS in 1959 5) . ARS is an acute illness characterized by four distinct clinical manifestations and syndromes, depending on the absorbed doses [6] [7] [8] [9] [10] [11] . The appearance of signs and symptoms of system incompetence according to the dose and latent period marks the onset of (a) cerebro-or cardiovascular syndrome, (b) gastrointestinal syndrome, (c) hematopoietic syndrome, and (d) respiratory symptom. The relationship between ARS and the clinical time course (latent period) is summarized in Table 3 10) . Although response of an organ is mandated primarily by the dosage received, this can be modulated by effects of other irradiated organs. For example, granulocytopenia allows for the development of bacterial invasion following epithelial loss to the irradiated gut.
We evaluate the present case regarding the signs and symptoms, as well as the treatment given to Patient A within the context of our general understanding of ARS.
(1) Prodromal syndrome
The prodromal phase consists of symptoms and signs appearing within the first 48 hours after irradiation 11) . Major signs and symptoms include vomiting, diarrhea, hyperthermia, erythema, hypotension, and neurologic dysfunction. All individuals subjected to lethal doses of radiation (10-100 Gy) have shown symptoms characteristic of this phase within five to 15 minutes. The prodromal phase is characterized by symptoms that are induced by the products of acute cell death, and by direct parasympathetically mediated neurogenic effects on the gastrointestinal and central nervous systems.
The onset within the first hour of explosive bloody diarrhea signals a fatal outcome. Appearance during the first 2 to 3 hours indicates a high dose. Onset between 6 to 12 hours and termination within 24 hours suggests a sublethal (1-2 Gy) dose. Gastrointestinal symptoms must be documented at the initial and each subsequent examination, and differentiated from a normal stress/ anxiety response.
A significant rise in the body temperature in the first hours after exposure is associated with a fatal outcome. Fever and chills within 24 hours indicate poor prognosis. A dose of 10 to 20 Gy causes erythema within the first 24 hours to exposed body surfaces, while this is less frequent and late in appearance for lower doses (4 Gy). Hypotension is associated with lethal whole body irradiation. A reduction in the systolic blood pressure of greater than 10% is considered to be significant. Mental confusion, ataxia, convulsion, and coma in the first 2 to 6 hours after exposure indicate a lethal dose. Careful attention to the time of onset and duration of these signs and symptoms are important to estimate the degree of radiation injuries.
Patient A manifested transient syncope immediately after exposure. He had vomiting within 10 minutes, and diarrhea within 20 minutes. He also developed skin erythema, hypotension of 86 mmHg systolic blood pressure and 38.5°C fever while complaining of chills during the first day.
His skin erythema appearance on the day of exposure indicated a high dose. He also showed transient loss of consciousness, exhaustion and muscle weakness, but no obvious sensory disturbances. There was, however, swelling in his right upper arm, and he complained of localized pain.
All of these signs and symptoms of Patient A's prodromal syndrome on the first day indicated fatal exposure.
(2) Cardiovascular/ CNS syndrome
There have been many debates and little data concerning the existence of either a cardiovas- In one accident, a man receiving inhomogeneous total-body irradiation with a total dose to the head of approximately 100 Gy mixed gamma and neutron radiation died after 35 hours. The heart (dose of about 120 Gy) showed interstitial myocarditis, which was considered to be the primary cause of death in this particular case 12) .
With a high dose of, 50-100 Gy or more exposure, immediate nausea, vomiting, bloody diarrhea, irreversible hypotension, apathy, ataxia, convulsion, and coma are seen without any latent phase. Progression to overt clinical illness occurs in 3 to 6 hours. Death occurs within 48 hours. Patient A did not show any of these manifestations, indicative of an extremely high-dose exposure.
(3) Gastrointestinal syndrome
Followed by prodromal syndrome, i.e., a prompt onset (3 to 12 hours) of profuse diarrhea, nausea, and vomiting, patients become asymptomatic after 24 to 48 hours with lymphocyte depression. After a latent period of 1 week or less, denudation of the GI tract occurs, leading to profuse diarrhea, fulminant fever, infection, and hemorrhage, with subsequent death or the onset of the hematopoietic syndrome. In humans, severe enteritis starts from approximately day 4 after exposure, exceeding 10 Gy, and from about day 7 for 6-10 Gy. In 757 documented deaths in Hiroshima and Nagasaki, the time course of death showed two clear peaks in frequency: one between days 6 and 9, and the other between days 20 and 30 13) . The first peak can likely be attributed to the gastrointestinal syndrome, and the second to the hemopoietic syndrome.
On the third day after exposure, Patient A's peripheral blood lymphocyte count reached null levels. On the seventh and eighth days after exposure, the patient underwent peripheral blood stem-cell transplantation from an HLA-identical female immediate family member. Table 4 summarizes the reported medications and treatment against gastrointestinal syndrome [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . 
(4) Hematopoietic Syndrome
Various reports have presented dose and time response curves for changes in the concentration of platelets, lymphocytes, and neutrophils in the peripheral blood of healthy humans receiving whole-body exposures [25] [26] [27] .
Early reductions in the absolute peripheral lymphocyte count (first few hours) last for several days to weeks. A rise in the leukocyte count for a few days follows, leveling off for a few days, then falling in the minimum level in 2 to 5 weeks. High doses of radiation cause severe granulocytopenia in 7 to 10 days and is an indicator of poor prognosis. Recovery can take weeks to months. In 1 to 2 weeks, the platelets count falls. Maximum depression occurs in 4 to 5 weeks. If radiation is massive, severe platelet reduction occurs earlier, which may take several months to return to normal levels.
Red blood cells show a slow decline with reticulocytopenia. The extent depends on the amount of radiation exposure and the severity of acute-radiation syndrome. Blood loss from the gastrointestinal tract or into tissues may lead to earlier anemia. Fig.1 and Table 5 summarize this case and previously reported clinical courses, medications and treatments against hematopoietic syndrome [28] [29] [30] [31] .
(5) Respiratory and pulmonary symptoms
Until the mid 1980s, patients receiving whole-body irradiation in excess of approximately 8 Gy did not survive long enough to allow an onset of radiation pneumonitis. The respiratory symptoms of ARS are induced at doses greater than approximately 5 Gy. Table 6 summarizes the reported medications and treatment against respiratory symptoms [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . The present case developed pleural effusion and pulmonary congestion on day 5 on CT examination, which worsened until the 10 th day to start intubation and artificial ventilation.
Patient A developed, despite aggressive diuretic therapy, aggravating pulmonary edema and hypoxemia, which required intubation and ventilator-assisted respiratory management, possibly because of uneven, but significantly high-dose, irradiation in the ventral side of the upper trunk with mixed neutron and γ -ray [1] [2] [3] . It was unclear whether the cause of hypoxemia had been radiation pneumonitis or congestive heart failure. The patient died before developing pulmonary fibrosis.
(6) Effect on skin
Effects on skin are important because they are dose-dependent and readily detected by inspection, and thus provide an approximate measure of injury with prognostic value. Erythema proceeds in waves. After exposure of greater than 10 Gy, there may be an initial phase which reaches a peak at around day 1 followed by a second wave between one and four weeks [43] [44] . Table 7 summarizes the reported medications and treatment against radiation skin injury [45] [46] [47] [48] [49] [50] [51] [52] . In the present case, the absorbed skin-dose distribution was very uneven and high. The recent calculation showed that the absorbed skin dose was highest at the upper-right abdomen, reaching 61.8 Gy (27.0 as neutrons plus 34.8 Gy as γ -rays). The dorsal side was calculated to have received one eighth of that of abdominal side, and a much smaller neutron component. The details of these estimations of the absorbed dose have just been published in Japanese 1) . Skin A TOKAI-MURA CRITICALITY ACCIDENT PATIENT S177 denudation gradually expanded from the upper abdomen to the face, trunk and most of the extremities. The skin did not recover despite cultured skin-cell grafts. Discharging from the skin increased from the 5 th to 9 th week and continued until his death.
(7) Bone-marrow transplants (BMT)
BMT have been utilized for bone-marrow reconstitution of radiation accident patients since the early 1950s. A total of 13 allogeneic BMTs and six fetal liver transplantations were performed in acutely injured victims of the Chernobyl disaster. In the absence of well-matched donors, deliberately mismatched bone-marrow transplants were administered to provide temporary coverage, with the intention of causing a "bridging effect". Only two of the seriously irradiated Chernobyl patients survived after BMT 53) . Flomenberg et al. reported umbilical-cord blood transplants in 1992 54) , which are now in daily clinical use. Lasky used peripheral blood, fetal liver, and cadavers as alternate sources of stem cell progenitors for transplant in 1991 55) .
Densow et al. reported clinical criteria for stem-cell transplantation based on data of the International Computer Database for Radiation Exposure Case Histories (ICDREC) 56) . Based on a clinical evaluation of the 58 most severely affected ARS patients (> 5 Gy), their recommendations were as follows: 1) When there is severe radiation damage to organs other than the hematopoietic system, patients can hardly be expected to benefit from stem-cell transplantation.
2) In the mid-lethal dose range (5-7 Gy), the application of growth factors seems to be promising, and again it should be carefully considered whether stem cell transplantation is indicated.
3) In the high-dose range, hematopoietic stem-cell transplantation (with temporary or permanent engraftment) is very likely to be the appropriate therapeutic option, provided that all prevailing state-of-the-art precautions are taken to minimize the risk for acute GVHD.
From the estimated dosage of irradiation and the declining profile of the peripheral lymphocyte count, we determined that the patient was indicated for early hematopoietic stem-cell transplantation and intensive care under aseptic conditions. On the seventh and eighth days after exposure, the patient underwent peripheral blood stem-cell transplantation from an HLA-identical female, who was an immediate-family member.
(8) Cytokines
As shown in Table 5 , the patient was administered with cytokines, some of which have not been used in daily clinical management [28] [29] [30] [31] . Cytokine therapy was first used in the treatment of accidentally irradiated subjects in the Chernobyl disaster. One of the cytokine combinations in current usage is recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3). Its use in a 1990 Israel accident (in combination with BMT) and in a 1991 Belarus accident the survival of two victims was prolonged by using these cytokines for several weeks beyond that anticipated 57, 68) . Tables 8 and 9 summarize the prognosis of victims due to major criticality accidents and *: +2 non-radiation deaths other radiation accidents. Patients exposed to 10 Gy or more in nuclear criticality accidents survived for no more than 9 days. The longest survival case documented for severe irradiation was 113 days for a patient irradiated with 10 Gy of 60 Co. Densow et al. reported from the data of ICDREC (49 death in 58 patients) that the main cause of death could be classified as follows: A) radiation burns (32 cases); B) gastro-intestinal damage, including GI hemorrhage (24 cases); C) infection (9 cases); D) adult respiratory distress syndrome (9 cases); E) acute graft-versus-host disease (7 cases), and F) other reasons (7 cases) 56) .
(9) Prognosis and cause of death
In our patient, gastrointestinal disorder, massive diarrhea and bleeding due to massive mucosal exfoliation in the digestive system worsened later, and were so extensive as to be fatal. Despite respiratory support, massive fluid infusion and blood transfusion, he finally died of MOF. In the past, the treatment options were limited primarily to the management of symptoms. In the present treatment, several new clinical interventions, such as SDD, BMT and cytokines, were administered under an aseptic environment. This type of high-level care requires a tremendous amount of human and material resources. The logistic questions and medical problems must be addressed in any future planning for medical emergencies involving radiation accidents. Many of them will not likely be soon resolved, since any new therapeutic modality could not be tested because of the rarity of such cases. Most studies remain at experimental stages using animals, and clinical reports are very few and anecdotal at best. Who benefits from the cytokine therapy? Is blood stem cell transplantation of one kind or another justified for the temporary relief in face of bone-marrow failure? Is there any way to regenerate tissues or stop the radiation skin damage and gastrointestinal bleeding? And will the time come when multi-potential embryonic stem-cell transplantation can be applied to this kind of patient? Above all, the greatest lesson that we learned was that there was little we could offer medically to these critically irradiated victims.
